Evaluating Standardization of Neoadjuvant Immunotherapy in Transplant-Eligible Hepatocellular Carcinoma Populations
DOI:
https://doi.org/10.35516/jmj.v59i1.3957Abstract
In the past decade, immunotherapy has significantly revolutionized the treatment of advanced hepatocellular carcinoma (HCC). Recent phase III trials examining immunotherapy as monotherapy and combination therapy for early to intermediate-stage HCC have produced favorable results, while further phase III trials in this patient cohort are ongoing. Owing to the advantageous data derived from these trials, the utilization of immunotherapy is broadening to include patients with earlier stages of HCC, especially within the transplant-eligible subgroup. Current literature increasingly advocates for the standardized application of neoadjuvant immunotherapy in liver transplantation. Transplantation functions as a potentially curative treatment for HCC and additionally restores normal, healthy liver function. Immunotherapy in pre-transplant patients may improve downstaging efficacy and tumor management, though it carries immunological risks. Immune-related toxicities are substantial in individuals with chronic liver disease, who are particularly susceptible, alongside the risk of acute rejection post-transplantation. The main goal of immunotherapy in this population is to improve access to liver transplantation while preserving pre- and post-transplant results. This concise review analyzes contemporary literature regarding the use of immunotherapy in the neoadjuvant context prior to liver transplantation, explores potential advantages of combination immunotherapy, and synthesizes important recent clinical findings from prominent trials related to HCC transplant oncology treatment.
References
Sung, H., et al., Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 2021. 71(3): p. 209-249.
Abdelrahim, M., et al., Transplant oncology: An emerging discipline of cancer treatment. Cancers, 2023. 15(22): p. 5337.
Abdelrahim, M. and A. Esmail, Transplant oncology and immunotherapy: Immunotherapy and liver transplants, in Transplant Oncology. 2025, Academic Press. p. 87-105.
Hargadon, K.M., C.E. Johnson, and C.J. Williams, Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol, 2018. 62: p. 29-39.
Rumgay, H., et al., Global burden of primary liver cancer in 2020 and predictions to 2040. Journal of Hepatology, 2022. 77(6): p. 1598-1606.
Rimassa, L., R.S. Finn, and B. Sangro, Combination immunotherapy for hepatocellular carcinoma. Journal of Hepatology, 2023. 79(2): p. 506-515.
Lee, S.K., et al., An Immunological Perspective on the Mechanism of Drug Induced Liver Injury: Focused on Drugs for Treatment of Hepatocellular Carcinoma and Liver Transplantation. International Journal of Molecular Sciences, 2023. 24(5): p. 5002.
Ruff, S.M., et al., Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma. Curr Oncol, 2023. 30(6): p. 5863-5875.
Rezaee-Zavareh, M.S., et al., Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis. Journal of hepatology, 2024.
Esmail, A. and M. Abdelrahim, History of cancer and transplant clearance: Considerations prior to transplantation, in Transplant Oncology. 2025, Academic Press. p. 215-228.
Abdelrahim, M., et al., Real-world (RW) experience with atezolizumab+ bevacizumab (A+ B) for the treatment of unresectable HCC (uHCC): A multicenter study. 2025, American Society of Clinical Oncology.
Abdelrahim, M., et al., Focal update on immunotherapy and liver transplantation in the era of transplant oncology. Current Oncology, 2024. 31(9): p. 5021-5026.
Abdelrahim, M., et al., Advances in Immunotherapy for Transplant Oncology. 2024, MDPI. p. 2369.
Esmail, A., et al., The Impact of Infections in Patients Treated with Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma. Journal of Clinical Medicine, 2024. 13(17): p. 4994.
Esmail, A., et al., The recent trends of systemic treatments and locoregional therapies for cholangiocarcinoma. Pharmaceuticals, 2024. 17(7): p. 910.
Esmail, A., et al., Cholangiocarcinoma: The Current Status of Surgical Options including Liver Transplantation. Cancers, 2024. 16(11): p. 1946.
Abdelrahim, M., et al., Utilization of Immunotherapy as a Neoadjuvant Therapy for Liver Transplant Recipients with Hepatocellular Carcinoma. Journal of Clinical Medicine, 2024. 13(11): p. 3068.
Abdelrahim, M., et al., Patient characteristics and evaluations prior to liver transplantation, in Transplant Oncology. 2025, Academic Press. p. 277-293.
Mazzaferro, V., et al., Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med, 1996. 334(11): p. 693-9.
Yao, F.Y., et al., Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl, 2002. 8(9): p. 765-74.
Mazzaferro, V., et al., Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol, 2009. 10(1): p. 35-43.
Duvoux, C., et al., Liver Transplantation for Hepatocellular Carcinoma: A Model Including α-Fetoprotein Improves the Performance of Milan Criteria. Gastroenterology, 2012. 143(4): p. 986-994.e3.
Sapisochin, G., et al., The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: A prospective validation study. Hepatology, 2016. 64(6): p. 2077-2088.
Mazzaferro, V., et al., Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma. Gastroenterology, 2018. 154(1): p. 128-139.
Lingiah, V.A., et al., Liver Transplantation Beyond Milan Criteria. J Clin Transl Hepatol, 2020. 8(1): p. 69-75.
Onaca, N., et al., Expanded criteria for liver transplantation in patients with hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in Liver Transplantation. Liver Transpl, 2007. 13(3): p. 391-9.
Silva, M., et al., Expanded criteria for liver transplantation in patients with cirrhosis and hepatocellular carcinoma. Liver Transpl, 2008. 14(10): p. 1449-60.
Kaido, T., et al., Usefulness of the Kyoto criteria as expanded selection criteria for liver transplantation for hepatocellular carcinoma. Surgery, 2013. 154(5): p. 1053-60.
Toso, C., et al., Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: A prospective validation. Hepatology, 2015. 62(1): p. 158-165.
Biolato, M., et al., Upper Limits of Downstaging for Hepatocellular Carcinoma in Liver Transplantation. Cancers (Basel), 2021. 13(24).
Ponniah, S.A., A.G. Zori, and R. Cabrera, Locoregional Therapies for Bridging and Downstaging Hepatocellular Carcinoma Prior to Liver Transplant, in Liver Cancer, C.M. Sergi, Editor. 2021, Exon Publications: Brisbane (AU).
Wassmer, C.H., et al., Immunotherapy and Liver Transplantation: A Narrative Review of Basic and Clinical Data. Cancers (Basel), 2023. 15(18).
Block, P.D., M. Strazzabosco, and A. Jaffe, Approach to immunotherapy for HCC in the liver transplant population. Clin Liver Dis (Hoboken), 2024. 23(1): p. e0158.
Amado, V., et al., Selecting patients with hepatocellular carcinoma for liver transplantation: incorporating tumor biology criteria. J Hepatocell Carcinoma, 2019. 6: p. 1-10.
Lehrich, B.M., et al., Battle of the biopsies: Role of tissue and liquid biopsy in hepatocellular carcinoma. J Hepatol, 2024. 80(3): p. 515-530.
Tzartzeva, K., et al., Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. Gastroenterology, 2018. 154(6): p. 1706-1718.e1.
Marrero, J.A., et al., Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology, 2018. 68(2): p. 723-750.
Vogel, A., et al., Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2018. 29(Suppl 4): p. iv238-iv255.
Rudnick, S.R. and M.W. Russo, Liver transplantation beyond or downstaging within the Milan criteria for hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol, 2018. 12(3): p. 265-275.
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol, 2018. 69(1): p. 182-236.
Mazzaferro, V., et al., Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial. The Lancet Oncology, 2020. 21(7): p. 947-956.
Abdelrahim, M., et al., Transplant Oncology: An Emerging Discipline of Cancer Treatment. Cancers (Basel), 2023. 15(22).
Mehta, N., et al., Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium. Gastroenterology, 2021. 161(5): p. 1502-1512.
Kang, E., et al., Stable liver graft post anti-PD1 therapy as a bridge to transplantation in an adolescent with hepatocellular carcinoma. Pediatr Transplant, 2022. 26(3): p. e14209.
Tabrizian, P., S.S. Florman, and M.E. Schwartz, PD-1 inhibitor as bridge therapy to liver transplantation? Am J Transplant, 2021. 21(5): p. 1979-1980.
Chen, G.H., et al., Pretransplant use of toripalimab for hepatocellular carcinoma resulting in fatal acute hepatic necrosis in the immediate postoperative period. Transpl Immunol, 2021. 66: p. 101386.
Chen, Z., et al., Prognosis after liver transplantation in patients treated with anti-PD-1 immunotherapy for advanced hepatocellular carcinoma: case series. Ann Palliat Med, 2021. 10(9): p. 9354-9361.
Dehghan, Y., et al., Rescue liver re-transplantation after graft loss due to severe rejection in the setting of pre-transplant nivolumab therapy. Clin J Gastroenterol, 2021. 14(6): p. 1718-1724.
Lizaola-Mayo, B.C., et al., Immunotherapy as a Downstaging Tool for Liver Transplantation in Hepatocellular Carcinoma. Am J Gastroenterol, 2021. 116(12): p. 2478-2480.
Aby, E.S. and J.R. Lake, Immune Checkpoint Inhibitor Therapy Before Liver Transplantation-Case and Literature Review. Transplant Direct, 2022. 8(4): p. e1304.
Nordness, M.F., et al., Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient? Am J Transplant, 2020. 20(3): p. 879-883.
Abdelrahim, M., et al., Immunotherapy as a Neoadjuvant Therapy for a Patient with Hepatocellular Carcinoma in the Pretransplant Setting: A Case Report. Curr Oncol, 2022. 29(6): p. 4267-4273.
Reig, M., et al., BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. Journal of Hepatology, 2022. 76(3): p. 681-693.
Singal, A.G., et al., AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology, 2023. 78(6): p. 1922-1965.
Huang, A.C., et al., National Experience on Waitlist Outcomes for Down-Staging of Hepatocellular Carcinoma: High Dropout Rate in All-Comers. Clin Gastroenterol Hepatol, 2023. 21(6): p. 1581-1589.
Degroote, H., et al., International study on the outcome of locoregional therapy for liver transplant in hepatocellular carcinoma beyond Milan criteria. JHEP Reports, 2021. 3(5).
Masior, Ł., et al., Alpha-Fetoprotein Response after First Transarterial Chemoembolization (TACE) and Complete Pathologic Response in Patients with Hepatocellular Cancer. Cancers (Basel), 2023. 15(15).
Seehofer, D., et al., Patient Selection for Downstaging of Hepatocellular Carcinoma Prior to Liver Transplantation-Adjusting the Odds? Transpl Int, 2022. 35: p. 10333.
Lai, Q., et al., Identification of an Upper Limit of Tumor Burden for Downstaging in Candidates with Hepatocellular Cancer Waiting for Liver Transplantation: A West–East Collaborative Effort. Cancers, 2020. 12(2): p. 452.
Kotwani, P., et al., DCP and AFP-L3 Are Complementary to AFP in Predicting High-Risk Explant Features: Results of a Prospective Study. Clinical Gastroenterology and Hepatology, 2022. 20(3): p. 701-703.e2.
Norman, J.S., et al., AFP-L3 and DCP strongly predict early hepatocellular carcinoma recurrence after liver transplantation. Journal of Hepatology, 2023. 79(6): p. 1469-1477.
Frankul, L. and C. Frenette, Hepatocellular Carcinoma: Downstaging to Liver Transplantation as Curative Therapy. J Clin Transl Hepatol, 2021. 9(2): p. 220-226.
Gu, Y., et al., When immunotherapy meets liver transplantation for hepatocellular carcinoma: A bumpy but promising road. Chin J Cancer Res, 2023. 35(2): p. 92-107.
Ouranos, K., et al., Role of immunotherapy in downsizing hepatocellular carcinoma prior to liver transplantation. World J Transplant, 2022. 12(11): p. 331-346.
Chamseddine, S., M. LaPelusa, and A.O. Kaseb, Systemic Neoadjuvant and Adjuvant Therapies in the Management of Hepatocellular Carcinoma-A Narrative Review. Cancers (Basel), 2023. 15(13).
Tsilimigras, D.I., et al., Recurrence Patterns and Outcomes after Resection of Hepatocellular Carcinoma within and beyond the Barcelona Clinic Liver Cancer Criteria. Ann Surg Oncol, 2020. 27(7): p. 2321-2331.
Chouik, Y., et al., Case Report: Successful liver transplantation after achieving complete clinical remission of advanced HCC with Atezolizumab plus Bevacizumab combination therapy. Front Immunol, 2023. 14: p. 1205997.
Wang, T., et al., Neoadjuvant programmed cell death 1 inhibitor before liver transplantation for HCC is not associated with increased graft loss. Liver Transpl, 2023. 29(6): p. 598-606.
Tabrizian, P., et al., Immunotherapy and Liver Transplantation: The Future or the Failure? Surg Clin North Am, 2024. 104(1): p. 163-182.
Natarajan, B., et al., Downstaging hepatocellular carcinoma before liver transplantation: A multicenter analysis of the "all-comers" protocol in the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) consortium. Am J Transplant, 2023. 23(11): p. 1771-1780.
Pelizzaro, F., F. Farinati, and F. Trevisani, Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Strategies and Biomarkers Predicting Response and/or Resistance. Biomedicines, 2023. 11(4).
Dong, Y., et al., Recent Advances and Future Prospects in Immune Checkpoint (ICI)-Based Combination Therapy for Advanced HCC. Cancers (Basel), 2021. 13(8).
Finn, R.S., et al., Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med, 2020. 382(20): p. 1894-1905.
Abou-Alfa, G.K., et al., Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. NEJM Evidence, 2022. 1(8): p. EVIDoa2100070.
Llovet, J.M., et al., Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 2008. 359(4): p. 378-90.
Cheng, A.-L., et al., Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. Journal of Hepatology, 2022. 76(4): p. 862-873.
Qin, S., et al., Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. The Lancet, 2023. 402(10408): p. 1133-1146.
Rizzo, A., et al., Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis. Curr Oncol, 2023. 30(1): p. 749-757.
Fulgenzi, C.A.M., et al., Efficacy and safety of frontline systemic therapy for advanced HCC: A network meta-analysis of landmark phase III trials. JHEP Reports, 2023. 5(5): p. 100702.
Remash, D., et al., Immune checkpoint inhibitor-related hepatotoxicity: A review. World J Gastroenterol, 2021. 27(32): p. 5376-5391.
Cataldi, M., F. Manco, and G. Tarantino, Steatosis, Steatohepatitis and Cancer Immunotherapy: An Intricate Story. Int J Mol Sci, 2021. 22(23).
Crocetti, L., et al., Locoregional Treatments for Bridging and Downstaging HCC to Liver Transplantation. Cancers, 2021. 13(21): p. 5558.
Yin, C., et al., Bridging and downstaging with TACE in early and intermediate stage hepatocellular carcinoma: Predictors of receiving a liver transplant. Ann Gastroenterol Surg, 2023. 7(2): p. 295-305.
Liu, H., et al., New insights into mechanisms and interventions of locoregional therapies for hepatocellular carcinoma. Chin J Cancer Res, 2024. 36(2): p. 167-194.
Brandi, N. and M. Renzulli, The Synergistic Effect of Interventional Locoregional Treatments and Immunotherapy for the Treatment of Hepatocellular Carcinoma. Int J Mol Sci, 2023. 24(10).
Cesario, S., et al., Evolving Landscape in Liver Transplantation for Hepatocellular Carcinoma: From Stage Migration to Immunotherapy Revolution. Life (Basel), 2023. 13(7).
Bajestani, N., et al., Examining the Efficacy and Safety of Combined Locoregional Therapy and Immunotherapy in Treating Hepatocellular Carcinoma. Biomedicines, 2024. 12(7).
Yoest, J.M., Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: a short review. ImmunoTargets and Therapy, 2017. 6(null): p. 73-82.
Passat, T., et al., Mécanismes physiopathologiques des effets secondaires des immunothérapies par anticorps anti-CTLA-4, anti-PD-1 et anti-PD-L1 dans le traitement du cancer. Bulletin du Cancer, 2018. 105(11): p. 1033-1041.
Johnson, D.B., et al., Fulminant Myocarditis with Combination Immune Checkpoint Blockade. N Engl J Med, 2016. 375(18): p. 1749-1755.
Berner, F., et al., Association of Checkpoint Inhibitor–Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non–Small Cell Lung Cancer. JAMA Oncology, 2019. 5(7): p. 1043-1047.
Gopalakrishnan, V., et al., Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients. Science, 2018. 359(6371): p. 97-103.
Matson, V., et al., The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients. Science, 2018. 359(6371): p. 104-108.
Chaput, N., et al., Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol, 2017. 28(6): p. 1368-1379.
Iwama, S., et al., Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody. Science Translational Medicine, 2014. 6(230): p. 230ra45-230ra45.
Kelley, R.K., et al., Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study. J Clin Oncol, 2021. 39(27): p. 2991-3001.
Yau, T., et al., Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial. JAMA Oncology, 2020. 6(11): p. e204564-e204564.
Murray-Lyon, I.M., et al., Treatment of bleeding oesophageal varices by infusion of vasopressin into the superior mesenteric artery. Gut, 1973. 14(1): p. 59-63.
Miah, A., et al., Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival. J Cancer Res Clin Oncol, 2023. 149(5): p. 2235-2242.
Patrinely, J.R., Jr., et al., A multicenter characterization of hepatitis associated with immune checkpoint inhibitors. Oncoimmunology, 2021. 10(1): p. 1875639.
Sanjeevaiah, A., T. Kerr, and M.S. Beg, Approach and management of checkpoint inhibitor-related immune hepatitis. J Gastrointest Oncol, 2018. 9(1): p. 220-224.
Aithal, G.P., et al., Guidelines on the management of ascites in cirrhosis. Gut, 2021. 70(1): p. 9-29.
Balcar, L., et al., Risk of further decompensation/mortality in patients with cirrhosis and ascites as the first single decompensation event. JHEP Rep, 2022. 4(8): p. 100513.
Xie, E., et al., Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. JAMA Oncol, 2023. 9(10): p. 1423-1431.
Costa, F., et al., Systemic treatment in patients with Child-Pugh B liver dysfunction and advanced hepatocellular carcinoma. Cancer Med, 2023. 12(13): p. 13978-13990.
Plaz Torres, M.C., et al., Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors and Applicability of First-Line Atezolizumab/Bevacizumab in a Real-Life Setting. J Clin Med, 2021. 10(15).
Mandlik, D.S., S.K. Mandlik, and H.B. Choudhary, Immunotherapy for hepatocellular carcinoma: Current status and future perspectives. World J Gastroenterol, 2023. 29(6): p. 1054-1075.
Cui, T.M., et al., Adverse Effects of Immune-Checkpoint Inhibitors in Hepatocellular Carcinoma. Onco Targets Ther, 2020. 13: p. 11725-11740.
Zhang, H., et al., Bevacizumab and wound-healing complications: a systematic review and meta-analysis of randomized controlled trials. Oncotarget, 2016. 7(50): p. 82473-82481.
Dorn, D.P., et al., Chemoembolization outcomes for hepatocellular carcinoma in cirrhotic patients with compromised liver function. HPB (Oxford), 2014. 16(7): p. 648-55.
Hodi, F.S., et al., Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. Jama, 2014. 312(17): p. 1744-53.
Hailemichael, Y., et al., Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell, 2022. 40(5): p. 509-523.e6.
Alturki, N.A., Review of the Immune Checkpoint Inhibitors in the Context of Cancer Treatment. J Clin Med, 2023. 12(13).
Donne, R. and A. Lujambio, The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma. Hepatology, 2023. 77(5): p. 1773-1796.
Li, S.Q., Y. Yang, and L.S. Ye, Angiogenesis and immune checkpoint dual blockade: Opportunities and challenges for hepatocellular carcinoma therapy. World J Gastroenterol, 2022. 28(42): p. 6034-6044.
Liu, Z.L., et al., Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment. Ther Adv Med Oncol, 2021. 13: p. 17588359211018026.
Zarlashat, Y., et al., Advancements in Immunotherapeutic Treatments for Hepatocellular Carcinoma: Potential of Combination Therapies. Int J Mol Sci, 2024. 25(13).
Panackel, C., et al., Immunosuppressive Drugs in Liver Transplant: An Insight. J Clin Exp Hepatol, 2022. 12(6): p. 1557-1571.
Luo, Y., et al., Immunotherapy in liver transplantation for hepatocellular carcinoma: Pros and cons. World J Gastrointest Oncol, 2022. 14(1): p. 163-180.
Wojtukiewicz, M.Z., et al., Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients and a new challenge for internists and general practitioners. Cancer Metastasis Rev, 2021. 40(3): p. 949-982.
Woo, S.M., et al., Immunotherapy Use Prior to Liver Transplant in Patients with Hepatocellular Carcinoma. Curr Oncol, 2022. 29(12): p. 9813-9825.
